Breast cancer and diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 10, 2010, Pages 673-677

  Schott, S ^a   Schneeweiss, A ^a   Sohn, C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

breast cancer; cancer; diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; FATTY ACID BINDING PROTEIN 4; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR SUBSTRATE; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SULFONYLUREA;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; HUMAN; INSULIN TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; SIGNAL TRANSDUCTION;

EID: 77956574493     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1254116     Document Type: Review

References (82)

1. Ahn J, Schatzkin A, Lacey JV, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007 167 2091-2102
2. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005 40 685-693
3. Baron JA, Weiderpass E, Newcomb PA, et al. Metabolic disorders and breast cancer risk (United States). Cancer Causes Control 2001 12 875-880
4. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008 300 2754-2764
5. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008 27 3576-3586
6. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002 3 565-574
7. Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010 123 S12-S18
8. Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010
9. Brown KA, Hunger NI, Docanto M, et al. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 2010
10. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007 67 6745-6752
11. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004 4 579-591
12. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003 348 1625-1638
13. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009 52 1755-1765
14. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 52 1766-1777
15. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006 296 193-201 (Pubitemid 44050373) (Pubitemid 44050373)
16. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004 140 945-950
17. Fierz Y, Novosyadlyy R, Vijayakumar A, et al. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 2010 59 686-693
18. Frankenberry KA, Skinner H, Somasundar P, et al. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 2006 28 985-993
19. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004 30 193-204
20. Frittitta L, Cerrato A, Sacco MG, et al. The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice. Breast Cancer Res Treat 1997 45 141-147
21. Frittitta L, Vigneri R, Stampfer MR, et al. Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype. J Cell Biochem 1995 57 666-669
22. Frystyk J, Skjaerbaek C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999 15 314-322
23. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010 16 1695-1700
24. Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 2008 26 833-834
25. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009 27 3271-3273
26. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2 - an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010 118 4-8
27. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 2008 68 329-337 (Pubitemid 351380136) (Pubitemid 351380136)
28. Hancke K, Grubeck D, Hauser N, et al. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010 119 367-367
29. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009 52 1732-1744
30. Hernandez-Diaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 2010
31. Hjalgrim H, Frisch M, Ekbom A, et al. Cancer and diabetes a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997 241 471-475
32. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009 52 2499-2506
33. Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 2010
34. Idris I. Observational registry database studies link insulin glargine with cancer risk. Diabetes Obes Metab 2009 11 910-912
35. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006 166 1871-1877
36. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56 106-130
37. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009 27 3297-3302
38. Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009 52 1745-1754
39. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002 94 606-616
40. Kusmic C, LAbbate A, Sambuceti G, et al. Improved myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J Cell Biochem 2010 109 1033-1044
41. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004 111 762-771 (Pubitemid 39062901) (Pubitemid 39062901)
42. Lai A, Sarcevic B, Prall OW, et al. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem 2001 276 25823-25833
43. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010 33 322-326
44. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007 121 856-862 (Pubitemid 47106217) (Pubitemid 47106217)
45. Lipscombe LL, Goodwin PJ, Zinman B, et al. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat 2006 98 349-356
46. Lipscombe LL, Goodwin PJ, Zinman B, et al. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008 109 389-395
47. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009 8 2031-2040
48. Maccio A, Madeddu C, Gramignano G, et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med 2010
49. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003 21 433-440
50. Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses Health Study. Diabetes Care 2003 26 1752-1758
51. Milazzo G, Giorgino F, Damante G, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992 52 3924-3930
52. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002 13 741-751
53. Mussig K, Haring HU. Insulin Signal Transduction in Normal Cells and its Role in Carcinogenesis. Exp Clin Endocrinol Diabetes 2010
54. Nardon E, Buda I, Stanta G, et al. Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer. J Clin Pathol 2003 56 599-604
55. Nguyen NP, Almeida FS, Chi A, et al. Molecular biology of breast cancer stem cells: Potential clinical applications. Cancer Treat Rev 2010
56. Novosyadlyy R, Lann DE, Vijayakumar A, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010 70 741-751
57. Nyholm H, Djursing H, Hagen C, et al. Androgens and estrogens in postmenopausal insulin-treated diabetic women. J Clin Endocrinol Metab 1989 69 946-949
58. Papa V, Pezzino V, Costantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990 86 1503-1510
59. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005 146 693-700
60. Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010 14 443-451
61. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008 371 569-578
62. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004 363 1346-1353
63. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004 5 153-165
64. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001 8 197-209
65. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001 104 517-529
66. Siddle K, Urso B, Niesler CA, et al. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001 29 513-525
67. Stumvoll M, Nawroth PP. The insulin glargine dilemma: an opportunity for the diabetes community? Diabetologia 2009 52 1987-1989
68. Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S, 20002002. Diabetes Care 2005 28 1599-1603
69. Taha C, Klip A. The insulin signaling pathway. J Membr Biol 1999 169 1-12
70. Taunk NK, Goyal S, Moran MS, et al. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 2010
71. Tsugane S, Inoue M. Insulin resistance and cancer: Epidemiological evidence. Cancer Sci 2010
72. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000 152 514-527
73. von Eynatten M, Liu D, Hock C, et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 2009 58 2093-2099
74. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007 8 395-408
75. Webster NJ, Resnik JL, Reichart DB, et al. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res 1996 56 2781-2788
76. Weiss HA, Brinton LA, Potischman NA, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 1999 28 816-823
77. Wolf I, Sadetzki S, Catane R, et al. Diabetes mellitus and breast cancer. Lancet Oncol 2005 6 103-111
78. Wolf I, Seger R. The mitogen-activated protein kinase signaling cascade: from bench to bedside. Isr Med Assoc J 2002 4 641-647
79. www.cancer.org
80. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007 86 s823-s835
81. Zarich SW. Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nat Rev Endocrinol 2009 5 500-506
82. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001 108 1167-1174